Association of maternal serum α-fetoprotein with persistent placenta previa

Koster, Erin L.; Dashe, Jodi S.; McIntire, Donald D.; Ramus, Ronald M.

doi:10.1080/14767050410001728935

Cited by 7 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several groups of researchers have investigated the role of the placenta in the transport and possible synthesis of AFP in situ [28,[69][70][71] following a report that AFP was synthesized by the first trimester human placenta [72]. These investigations sought to probe for the placental expression of AFP in trophoblast cells of normal pregnancies at full term.…”

Section: Afp and Afp-receptor Expression In The Normal Human Placentamentioning

confidence: 98%

Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family

Mizejewski

2010

Tumor Biol.

View full text Add to dashboard Cite

The identification of a receptor for alpha-fetoprotein (AFP) has long been sought in the field of medicine. The uptake and endocytosis of AFP by rat tumor cells in 1984 sparked a series of confirmatory reports and the original studies were then extended to include multiple tumor types in rats, mice, and humans. The following year, French investigators partially characterized the binding properties of the AFP receptor, but they were not able to purify the receptor. It was not until 1991-1992 that an AFP receptor was partially purified and characterized from both human monocytes and breast cancer cells. By 1993, a monoclonal antibody had been raised against the AFP receptor produced from a breast cancer extract with claims that the receptor was a widespread (universal) oncofetal biomarker for cancer. However, that receptor has yet to be cloned and/or purified due to its complex multimeric binding interactions and associations. The present report will review the literature of the multiple putative AFP receptors described to date, the cellular uptake and endocytosis of AFP, and the biochemical characterization of these putative cell-surface proteins. In addition, evidence derived from computer modeling, proteolytic degradation patterns, and amino acid sequence analysis will be presented in a proposed identification of a family of multi-ligand binding receptors; this family fits many, if not most, of the criteria required for an AFP receptor. The purposed receptor protein family is tentatively identified as the Scavenger receptors which comprise several classes of single- and double-pass integral transmembrane proteins. Present data do not support the concept that the AFP receptor is a "universal" tumor receptor and/or biomarker.

show abstract

Section: Afp and Afp-receptor Expression In The Normal Human Placentamentioning

confidence: 98%

Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family

Mizejewski

2010

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…MSα‐FP of 1.5 MoM or above had a sensitivity of 29% and a false positive rate of 10% to predict abruption. Koster et al showed an association between elevated increasing MSα‐FP values and greater likelihood of persistent placenta praevia at term. Both Kupferminc et al and Zelop et al retrospectively analysed serum MSα‐FP levels in women that underwent caesarean hysterectomies for placenta accreta, percreta or increta and matched them to controls that underwent caesarean hysterectomies for other reasons.…”

Section: Second Trimester Markersmentioning

confidence: 99%

Maternal serum analytes as markers of adverse obstetric outcome

Lakhi

Govind

Moretti

et al. 2012

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content Screening for Down syndrome is available in the first or second trimester. In the absence of aneuploidy and structural anomalies, abnormal maternal serum levels of first and second trimester markers are associated with adverse obstetric outcome. As the number of markers increases and their value becomes more extreme the likelihood of adverse obstetric outcome increases. Although many of the associations between maternal serum markers for adverse maternity outcome are statistically significant, the positive predictive value for individual outcomes are too low for them to be clinically useful as screening tests. Potential management strategies for care of women with abnormal serum markers are yet to be established. Pregnancies complicated by pre‐eclampsia, fetal growth restriction, pre‐term delivery, fetal demise and spontaneous miscarriage have been associated with abnormal deviations in either one or several components of these markers. Learning objectives To review the relationship between abnormal first and second trimester maternal markers and adverse obstetric outcomes. Ethical issues Despite evidence of increased pregnancy complications with unexplained abnormal quadruple screen, the optimal method to manage them is unclear. The cost of screening and emotional anxiety caused to patients must be outweighed by the benefits of early detection and the ability to reduce the overall risk. It is a great dilemma for obstetricians on how to proceed when confronted with an unexplained abnormal serum screen.

show abstract

“…The authors of several studies have investigated the role of the placenta in the transport and possible synthesis of ATP in situ (77)(78)(79)(80), since an earlier report showed that AFP was synthesized by the firsttrimester human placenta (81). The objective of these investigations was to probe for the placental expression of AFP and its receptor in trophoblast cells of normal pregnancies at full term.…”

Section: Structural and Functional Aspects Of Afpmentioning

confidence: 98%

Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome

Mizejewski

2007

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

The many physiologic roles of human alpha-fetoprotein (HAFP) and its correlation with perinatal distress/pregnancy outcome are rarely addressed together in the biomedical literature, even though HAFP has long been used as a biomarker for fetal birth defects. Although the well being of the fetus can be monitored by the measurement of gestational age-dependent HAFP in biologic fluid levels (serum, amniotic fluid, urine, and vaginal fluids) throughout pregnancy, the majority of clinical reports reflect largely second trimester and (less likely) first trimester testing due to regulatory clinical restrictions. However, reports of third-trimester and pregnancy term measurement of HAFP levels performed in clinical research and/or investigational settings have gradually increased over the years and have expanded our base knowledge of AFP-associated pregnancy disorders during these stages. The different structural forms of HAFP (isoforms, epitopes, molecular variants, etc.) detected in the various biologic fluid compartments have been limited by antibody recognition of specific epitopic sites developed by the kit manufacturers based on antibody specificity, sensitivity, and precision. Concomitantly, the advances in elucidating the various biologic actions of AFP are opening new vistas toward understanding the physiologic roles of AFP during pregnancy. The present review surveys HAFP as a biomarker for fetal distress during the perinatal period in view of its structural and functional properties. An attempt is then made to relate the AFP fluid levels to adverse pregnancy complications and outcomes. Hence, the present review was divided into two major sections: (I) AFP structure and function considerations and (II) the relationship of AFP levels to the distressed fetus during the third trimester and at term.

show abstract

Association of maternal serum α-fetoprotein with persistent placenta previa

Abstract: There is an association between increasing MSAFP values and greater likelihood of persistent placenta previa. An MSAFP value <1 MoM is associated with a reduction in the risk of persistence of previa to delivery.

Cited by 7 publications

References 10 publications

Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family

Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family

Maternal serum analytes as markers of adverse obstetric outcome

Physiology of Alpha-Fetoprotein as a Biomarker for Perinatal Distress: Relevance to Adverse Pregnancy Outcome

Contact Info

Product

Resources

About